Redesigning Commercial Model for Rare Disease: Understanding the Patient to Structure for Success
Rare Disease products account for half of all FDA approvals, most with fast-track designations, which means compressed launch timelines and increasingly competitive markets with smaller patient populations. The traditional commercial playbook has been upended, commercial success requires a deep understanding of the rare disease patient journey, caregiver, and HCP needs. Pharmaceutical manufacturers must be willing to examine their commercial infrastructure and build critical capabilities, to ensure product access and support that meets the patient and HCP needs. Herspiegel Consulting's commercial experts share a framework developed from 100+ pharmaceutical product launches.
Join us for this webinar to learn best practices for:
- Commercial infrastructure
- Developing deeper patient understanding and engagement
- Designing more impactful HCP interactions
- Operationalizing strategies for product access
If you are developing assets for rare disease indications, take advantage of this presentation to learn how to ensure your commercial organization is set up for success.